Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China; Department of Hepatobiliary Surgery, The First Affiliated Hospital, Wenzhou Medical University, Wenzhou, China.
Eur J Surg Oncol. 2022 Jun;48(6):1348-1355. doi: 10.1016/j.ejso.2021.12.466. Epub 2021 Dec 29.
Microvascular invasion (MVI) is a significant risk factor affecting survival outcomes of patients after R0 liver resection (LR) for hepatocellular carcinoma (HCC). The current classification of MVI is not refined enough to prognosticate long-term survival of these patients, and a new MVI classification is needed.
Patients with HCC who underwent R0 LR at the Eastern Hepatobiliary Surgery Hospital from January 2013 to December 2013 and with resected specimens showing MVI were included in this study with an aim to establish a novel MVI classification. The classification which was developed using multivariate cox regression analysis was externally validated.
There were 180 patients in the derivation cohort and 131 patients in the external validation cohort. The following factors were used for scoring: α-fetoprotein level (AFP), liver cirrhosis, tumor number, tumor diameter, MVI number, and distance between MVI and HCC. Three classes of patients could be distinguished by using the total score: class A, ≤3 points; class B, 3.5-5 points and class C, >5 points with distinct long-term survival outcomes (median recurrence free survival (mRFS), 22.6, 10.2, and 1.9 months, P < 0.001). The predictive accuracy of this classification was more accurate than the other commonly used classifications for HCC patients with MVI. In addition, the mRFS of class C patients was significantly prolonged (1.9 months vs. 6.2 months, P < 0.001) after adjuvant transcatheter arterial chemoembolization (TACE).
A novel MVI classification was established in predicting prognosis of HCC patients with MVI after R0 LR. Adjuvant TACE was useful for class C patients.
微血管侵犯(MVI)是影响肝癌患者 R0 肝切除(LR)后生存结局的重要危险因素。目前的 MVI 分类不够精细,无法预测这些患者的长期生存,因此需要一种新的 MVI 分类。
本研究纳入了 2013 年 1 月至 2013 年 12 月在东方肝胆外科医院行 R0 LR 且切除标本显示 MVI 的 HCC 患者,旨在建立一种新的 MVI 分类。使用多变量 Cox 回归分析开发的分类在外部进行了验证。
在推导队列中有 180 例患者,在外部验证队列中有 131 例患者。评分采用的因素有:甲胎蛋白(AFP)水平、肝硬化、肿瘤数量、肿瘤直径、MVI 数量以及 MVI 与 HCC 之间的距离。使用总评分可以将患者分为 3 个等级:A 级,≤3 分;B 级,3.5-5 分;C 级,>5 分,具有明显的长期生存结果(中位无复发生存期(mRFS),分别为 22.6、10.2 和 1.9 个月,P<0.001)。该分类的预测准确性优于其他常用于 MVI 肝癌患者的分类。此外,C 级患者的 mRFS 经辅助经导管动脉化疗栓塞(TACE)后显著延长(1.9 个月 vs. 6.2 个月,P<0.001)。
建立了一种新的 MVI 分类,可预测 R0 LR 后 MVI 肝癌患者的预后。辅助 TACE 对 C 级患者有用。